Аннотация:
This article presents an overview of data of Russian and foreign literature on possible associations between cognitive impairment and atrial fibrillation (AF). It includes modern classification of cognitive impairment, mechanisms of the effect of AF on cognitive functions and development of dementia, recommendations for the prevention of cognitive impairment in patients with AF. Special attention is paid to the assessment of cognitive status, and safe anticoagulant therapy, which is a priority in the prevention of cognitive impairment in patients with AF. Analysis of literature showed greater efficacy and safety of drugs from the group of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC), rivaroxaban in particular, in comparison with warfarin. Drugs from the NOAC group can be recommended for prevention stroke, cognitive impairment and dementia in elderly patients with AF. © 2018 Media Sphera Publishing Group. All rights reserved.
Ключевые слова:
Atrial fibrillation; Cognitive function; Dementia; Elderly age; Neurocognitive decline; Non-Vitamin K antagonist oral anticoagulants (noac); Rivaroxaban
anticoagulant agent; rivaroxaban; warfarin; aged; atrial fibrillation; cognition; cognitive defect; complication; dementia; human; oral drug administration; pathophysiology; risk factor; Russian Federation; Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cognition; Cognitive Dysfunction; Dementia; Humans; Risk Factors; Rivaroxaban; Russia; Warfarin
Остроумова О. Д. Ольга Дмитриевна 1968-
Черниаева М. С.
Головина О. В.
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Cherniaeva M. S.
Golovina O. V.
Atrial fibrillation as risk factor for development of cognitive function impairment and dementia. potential of anticoagulant therapy in their prevention
Atrial fibrillation as risk factor for development of cognitive function impairment and dementia. potential of anticoagulant therapy in their...
Текст визуальный непосредственный
Кардиология
Общество специалистов по сердечной недостаточности
Т. 58, Вып. 9 С. 76-88
2018
Обзор
Atrial fibrillation Cognitive function Dementia Elderly age Neurocognitive decline Non-Vitamin K antagonist oral anticoagulants (noac) Rivaroxaban
anticoagulant agent rivaroxaban warfarin aged atrial fibrillation cognition cognitive defect complication dementia human oral drug administration pathophysiology risk factor Russian Federation Administration, Oral Aged Anticoagulants Atrial Fibrillation Cognition Cognitive Dysfunction Dementia Humans Risk Factors Rivaroxaban Russia Warfarin
This article presents an overview of data of Russian and foreign literature on possible associations between cognitive impairment and atrial fibrillation (AF). It includes modern classification of cognitive impairment, mechanisms of the effect of AF on cognitive functions and development of dementia, recommendations for the prevention of cognitive impairment in patients with AF. Special attention is paid to the assessment of cognitive status, and safe anticoagulant therapy, which is a priority in the prevention of cognitive impairment in patients with AF. Analysis of literature showed greater efficacy and safety of drugs from the group of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC), rivaroxaban in particular, in comparison with warfarin. Drugs from the NOAC group can be recommended for prevention stroke, cognitive impairment and dementia in elderly patients with AF. © 2018 Media Sphera Publishing Group. All rights reserved.